UPDATE: Aeterna Zentaris Affirms Business, Prospects Remain Fundamentally Strong

Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), affirms that its business and prospects remain fundamentally strong and highlights the following developments:Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to continue the ZoptEC Phase 3 clinical program to completion following review of the final interim efficacy and safety data Zoptrex™ met Phase 2 Primary Endpoint in men with heavily pretreated castration- and Taxane-resistant prostate cancer First patient enrolled in the confirmatory Phase 3 clinical trial of Macrilen™ Promotion of Saizen® and EstroGel® by the Company's sales force continues to show promise Dilution from Series B Share Purchase Warrants has been substantially eliminatedCommenting about the fundamentals of the Company's business, Chairman, President and Chief Executive Officer David A Dodd stated, "Yesterday's announcement regarding corporate developments, which was required by IIROC on behalf of the Toronto Stock Exchange, caused some to question the fundamentals of our business. I want to reiterate that we believe the fundamentals remain strong. We have two products in Phase 3. One of the products, Zoptrex™, is in the late stage of Phase 3. We instituted a confirmatory Phase 3 clinical trial of Macrilen™ after a panel of US and EU endocrinology experts advised us to continue See full press release